Archives: Agenda

• Optimizing clinical research through effective technological integration
• A case study from the University of Berkeley scientists on how they’ve successfully implemented technology in drug development

• Working with both cooperative groups and biotechs in a harmonious way
• How to streamline processes and improve trial design
• Avoiding pitfalls which can have lasting global impacts
• Setting up trials for offsite patients and ensuring remote data can be obtained

• How decentralized and hybrid solutions can be used to increase patient access to clinical trials
• In-home visits have benefits for participants, sites and sponsors
• How to ensure uptake and adoption to drive global results
• What’s next for the hybrid trial model

• Overviewing the current political landscape and understanding what the impact is on small biotech’s
• Adapting to change by effectively navigating a small biotech though uncertainty
• Understanding and leveraging new start-up opportunities by reviewing investment and marketing trends

Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon giftcards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!

• Move from siloed to integrated with a collaborative framework and culture
• Build an agile operating model for immediate and long-term success
• Unlock the value of strategic FSP: key examples of success

• Utilize multi-omics data from next-generation sequencing to build a smarter, data-driven trial design.
• Accelerate patient matching and enrollment through our extensive clinical trial site network.
• Combine these capabilities in an integrated ecosystem to build a better, more efficient clinical trial.

• In rare populations, every patient carries significant weight, making retention more critical than in most other therapeutic areas.
• Because patient numbers are extremely limited, attrition cannot be absorbed—losing even a single participant can jeopardize the entire study.
• Rare disease trials often focus heavily on recruitment, but retention is equally essential and frequently overlooked.
• Collaboration with the Community is key
• Case studies